Teva’s Weltruza Wins FDA Approval as First Once-Monthly Under-the-Skin Olanzapine for Schizophrenia
Weltruza is the first monthly subcutaneous olanzapine for schizophrenia, with no loading dose and no post-shot clinic monitoring.
/ 6 items
#TEVA↓
Teva’s Anti-IL-15 Antibody Meets Main Goal in Celiac Disease Study
Teva’s TEV ’408 met its Phase 2a primary endpoint in celiac disease, limiting gluten-induced intestinal damage after one subcutaneous dose.
FDA Accepts Alvotech’s AVT16 – A New Interchangeable Biosimilar to Entyvio
Alvotech’s AVT16 biosimilar to Entyvio is under FDA review, aiming for cheaper, interchangeable treatment for gut diseases.
Teva Beats Q1 2026 Forecasts as AUSTEDO & UZEDY Surge — Acquires Emalex for $700M Tourette Drug
Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.
Corcept Therapeutics Stock Drops After Losing Patent Appeal to Teva
Corcept Therapeutics shares fell sharply to $29.71 in morning trading, following a Federal Circuit ruling affirming no patent infringement by Teva's generic version of Korlym.
Teva Pharmaceuticals Beats Q3 Expectations as Branded Drug Strategy Pays Off
Teva Pharmaceuticals (TEVA) Q3 2025 earnings beat expectations with 33% growth in branded drugs led by Austedo. Stock surges 12% as innovative portfolio drives transformation.